This biotech firm has room to run, even as its drug royalties are set to shrink

Piper Sandler said Biogen could face lower royalties on Ocrevus after its patent expires, creating a modest headwind to future revenue. The firm also noted Biogen has developed other medicines that should support growth, partially offsetting the patent-related pressure. Overall, the update is a measured positive on diversification despite the Ocrevus expiry risk.

Analysis

Piper Sandler said Biogen could face lower royalties on Ocrevus after its patent expires, creating a modest headwind to future revenue. The firm also noted Biogen has developed other medicines that should support growth, partially offsetting the patent-related pressure. Overall, the update is a measured positive on diversification despite the Ocrevus expiry risk.